Distinct expression and activity of GSK-3 and GSK-3β in prostate cancer
International Journal of Cancer, 04/27/2012
Darrington RS et al. – The observations highlight the importance of the glycogen synthase kinase (GSK–3)/androgen receptor (AR) signaling axis in prostate cancer and support the case for development of isoform–specific GSK–3 inhibitors and their use, in combination with AR antagonists, to treat patients with prostate cancer.



